Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kaufen / Verkaufen

Top-Partner CFD-Broker

Plus500
  • Keine Kommissionen, enge Spreads
  • Hebel- und Long/Short-Trading, fortgeschrittene Analysetools, kostenlose Echtzeitkurse etc.
  • CFD-Trading auf Aktien, Indizes, Krypto, Rohstoffe und Devisen
Direkt zu Plus500 CFD service. Ihr Kapital unterliegt einem Risiko.

Premium-Partner

IG Bank
  • Ein weltweit führender CFD-Anbieter*, FINMA-reguliert
  • Über 17'000 Märkte: Indizes, Devisen, Rohstoffe, Aktien, Kryptowährungen, Optionen und mehr
  • Erweiterte Handelszeiten und Wochenendhandel
  • Schweizer Kundenserviceteam, mit Büros in Genf und Zürich
*Die IG Gruppe ist grösster Anbieter nach Umsatz (veröffentlichter Geschäftsbericht 2022)
Direkt zur IG Bank Verluste können Einlagen übersteigen.
Saxo Bank
  • Lizenzierte Schweizer Bank (FINMA)
  • Keine Depotgebühren bei aktivierter Wertpapierleihe
  • Aktien, ETFs, Optionen, FX, CFDs, Futures, Rohstoffe, Bonds, Mutual Funds - auf einer Plattform
  • Gratis Expertenanalysen und Trading-Signale
  • Saxo Deal: Rückerstattung der Courtagen bis CHF 200 während 90 Tagen
Direkt zur Saxo Bank
Werbung
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
12.12.2024 09:00:04

EQS-News: BRAIN Biotech AG Sharpens Focus on Profitable Growth

BRAIN Biotech
3.97 CHF 87.21%
Kaufen / Verkaufen

EQS-News: BRAIN Biotech AG / Key word(s): Capital Markets Day
BRAIN Biotech AG Sharpens Focus on Profitable Growth

12.12.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


BRAIN Biotech AG Sharpens Focus on Profitable Growth

  • Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts
  • Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D ratio
  • Significant improvement in the liquidity and earnings situation due to the two completed transactions with Royalty Pharma and Akribion Therapeutics
  • Significant future potential through licensing of further BioIncubator and research projects

ZWINGENBERG, Germany, December 12, 2024 – BRAIN Biotech AG is creating the new growth segment BRAINBiocatalysts in the new financial year 2024/2025. The company announces this at today’s Fifth Capital Markets Day in Zwingenberg. By combining the two previous segments BioProducts and BioScience Zwingenberg, BRAIN Biotech is further sharpening its focus on the enzyme business and ensuring a more efficient integration of its research activities. The successful commercialization of the BioIncubator programs will be continued, thereby further strengthening the company's liquidity position and profitability.

"We already have a unique product portfolio of enzymes and related activities in highly attractive niches that cannot be served efficiently by larger providers. Bundling our production and research activities on a joint technology platform will take us another major step forward," says Adriaan Moelker, CEO of BRAIN Biotech AG, at the Capital Markets Day. "We are now focusing even more strongly on the successful implementation of our operational growth strategy and on consistently seizing opportunities," said Moelker. "Our vision is to become a top 10 innovative enzyme player with reliable profitable sales growth and positive cash flows, our strong science foundation will help us reach this vision."

The company is updating its medium-term forecast and now expects revenue of EUR 100 million in five years for the BRAINBiocatalysts segment alone. This corresponds to forecast growth of over 80 % in total compared to the 2022/23 financial year (comparable figure for the Group: EUR 55.3 million). The adjusted EBITDA margin in the segment is expected to grow to 15 %. The planning is based on a continued high Group R&D ratio of 7 – 10 %. Growth is expected to be predominantly organic. Strategically bolt-on acquisitions can add product expertise and accelerate the growth trajectory.

The BRAINBioIncubator represents the second segment of BRAIN Biotech AG. Due to the recently signed transactions with Royalty Pharma and Akribion Therapeutics GmbH, the commercial harvesting phase in the more volatile project business has now begun. The company expects the ongoing commercialization of the pipeline to have significant additional positive effects on BRAIN-Group sales and adjusted EBITDA over the next five years.

Michael Schneiders, CFO of BRAIN Biotech AG, explains: "The bundling of our continuous growth business in the new segment BRAINBiocatalysts emphasizes our company's focus on sustainable, profitable growth. In my opinion, we are also establishing now a valuation cornerstone for the company that is ideally complemented by the existing and future opportunities with high value potential from the BRAINBioIncubator segment." 

+++

About BRAIN Biotech

BRAIN Biotech AG is a leading provider of integrated solutions and products in the field of industrial biotechnology. The company specializes in enzymes and proteins, microbial production strains and bioprocesses for biotechnological production methods. BRAIN Biotech focuses on the growth markets of nutrition and life sciences as well as on innovative solutions for environment issues. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. Its business activities are divided into three segments: 1. BioProducts: Production and sale of specialty enzymes and proteins; 2. BioScience: Customized solutions based on enzyme engineering, production strain and bioprocess development, and screening for bioactive compounds; 3. BioIncubator: Pipeline of research-intensive development projects. For production, the Group operates fermentation plants in the UK and other production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 310 people and generated revenues of EUR 55.3 million in the fiscal year 2022/23. For more information, please visit www.brain-biotech-group.com .

 

Contact Media

Dr Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
E-mail: stk@brain-biotech.com

 

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
E-mail: ms@brain-biotech.com

 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations and assumptions of the management of BRAIN Biotech AG and are based on information currently available to management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

 

 



12.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.com
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2049495

 
End of News EQS News Service

2049495  12.12.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2049495&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6

Analysen zu BRAIN Biotech AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Die Assetklasse Private Debt erklärt | BX Swiss TV

Private Debt: Die rasant wachsende Anlageklasse mit grossem Potenzial für Investoren und Unternehmen!

Im Experteninterview mit Kirsten Bode von Muzinich & Co und Olivia Hähnel von der BX Swiss erfahren Sie, warum Private Debt eine spannende Alternative zur traditionellen Kreditfinanzierung ist. Die Anlageklasse ermöglicht Investoren eine sinnvolle Diversifikation, bietet attraktive Illiquiditätsprämien und zeichnet sich durch eine geringe Volatilität aus. Gleichzeitig profitieren mittelständische Unternehmen von flexiblen Finanzierungslösungen, um Wachstum und Projekte voranzutreiben. Insbesondere in Europa hat sich der Markt in den letzten zehn Jahren verdreifacht und bietet über neue Fondsmodelle auch Privatanlegern Zugang. 2025 könnte ein entscheidendes Jahr für Private Debt werden – dank sinkender Zinsen und steigender Nachfrage. Ein absolutes Muss für alle, die ihre Anlagestrategie um zukunftsträchtige Optionen erweitern wollen!

 

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Die Assetklasse Private Debt erklärt | BX Swiss TV

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’193.70 18.70 BU2SYU
Short 12’413.38 13.92 UBS07U
Short 12’906.61 8.72 0MSSMU
SMI-Kurs: 11’694.43 13.12.2024 17:31:19
Long 11’181.00 18.70 SSRM9U
Long 10’945.82 13.59 SSQMQU
Long 10’484.30 8.89 SS5M5U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Börse aktuell - Live Ticker

Verhaltener Wochenausklang: Wall Street letztlich stabil -- SMI geht schwächer ins Wochenende -- DAX schliesst nach Rekordhoch knapp unter Nulllinie -- Letztlich klare Abgaben in China und Japan

Der heimische Aktienmarkt zeigte sich am Freitag schwächer und auch der deutsche Leitindex fiel nach dem Erreichen eines neuen Allzeithochs schlussendlich wieder unter sein Vortagesniveau zurück. Die US-Börsen präsentierten sich zum Wochenschluss unentschlossen. An den asiatischen Börsen ging es am Freitag abwärts.

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten